RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Il colangiocarcinoma: approccio terapeutico basato su nuove acquisizioni di biologia cellulare e molecolare.
• 2 - COMPLICANZE OSTETRICHE DA ANTICORPI ANTI-FOSFOLIPIDI: meccanismi patogenetici molecolari quali nuovi target terapeutici e marcatori prognostici.
• 3 - CONTROLLO DEL CICLO CELLULARE DA LIGANDI DI RECETTORI NUCLEARI
• 4 - Isolamento e caratterizzazione molecolare e funzionale delle cellule staminali leucemiche (LSCs) per lo sviluppo di nuove strategie terapeutiche.
• 5 - IMMUNITA' INNATA E MALATTIA CELIACA
• 6 - Medulloblastoma: studio delle vie molecolari di sviluppo e progressione tumorale allo scopo di identificare approcci terapeutici innovativi
• 7 - Ruolo dell'FGFR2 e di altri cofattori nell'etiopatogenesi di tumori epiteliali.
• 8 - Un modello pre-clinico di terapia antitumorale e rigenerazione ossea con cellule staminali mesenchimali geneticamente modificate
• 9 - Il fattore di trascrizione NF-kB nella regolazione del differenziamento ed apoptosi del sistema immune.
• 10 - Estrogeni, recettori steroidei e carcinoma prostatico: modulazione dei meccanismi biomolecolari coinvolti nella progressione e metastatizzazione del tumore

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • GENETICA MEDICA
  • ONCOLOGIA MEDICA
  • MEDICINA INTERNA
  • GASTROENTEROLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

Classificazione geografica

• Regione: Marche

Bibliografia

1. Khan SA, Thomas HC, Davidson BR,Taylor-Robinson SD: Cholangiocarcinoma. Lancet 2005, 366 (8): 1303-1314.
2. Gores GJ: Cholangiocarcinoma: current concepts and insights. Hepatology 2003, 37: 961-969.
3. Blendis L, Halpern Z: An increasing incidence of cholangiocarcinoma: why? Gastroenterology 2004, 127: 1008-1009.
4. Alpini A, Alvaro D, Marzioni M, LeSage G, LaRusso N: The pathophysiology of Biliary Epithelia. Landes Bioscience. Eurekah.com. 2004.
5. Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, Ota H, Yoshioka S, Kato H, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Wakasa K, Monden M. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep. 2006 Mar;15(3):525-32
6. Alvaro D, Invernizzi P, Onori P, Franchitto A, De Santis A, Crosignani A, Sferra R, Ginanni-Corradini S, Mancino MG, Maggioni M, Attili AF, Podda M, Gaudio E: Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol 2004, 41: 905-912.
7. Alvaro D, Alpini G, Onori P, Perego L, Svegliati Baroni G, Franchitto A, Baiocchi L, Glaser SS, Le Sage G, Folli F, Gaudio E: Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology 2000, 119: 1681-1691.
8. Alvaro D, Alpini G, Onori P, Franchitto A, Glaser SS, Le Sage G, Gigliozzi A, Attili AF, Gaudio E: Effect of ovariectomy on the proliferative capacity of intrahepatic biliary epithelium. Gastroenterology 2002, 123: 336-344.
9. Alvaro D, Drudi Metalli V, Alpini G, Onori P, Franchitto A, Barbaro B, Glaser SS, Francis H, Cantafora A, Blotta I, Attili AF and Gaudio E: The intrahepatic biliary epithelium is a target of the growth hormone/insulin like growth factor 1 axis. J Hepatology 2005;43:875-83
10. Alvaro D, Onori P, Torrice A, Cardinale V, Alpini G, Franchitto A, Battisti G, Jefferson DM, angelici M, Strazzabosco M, Attili AF, Gaudio E. Estrogens and IGF1 promote the proliferation of hepatic cyst epithelium in autosomal dominant polycystic kidney disease (APDK). Journal of Hepatology, October 2005.
11. Garvin S, Nilsson UW, Huss FR, Kratz G, Dabrosin C. Estradiol increases VEGF in human breast studied by whole-tissue culture. Cell Tissue Res. 2006 Mar 28; [Epub ahead of print]
12. Reinmuth N, Liu W, Fan F, Jung YD, Ahmad SA, Stoeltzing O, Bucana CD, Radinsky R, Ellis LM. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res. 2002;8:3259-69
13. Gaudio E, Barbaro B, Alvaro D, Glaser S, Francis H, Ueno Y, Meininger C, Franchitto A, Onori P, Marzioni M, Taffetani S, Fava G, Stoica J, Venter J, Reichenback R, Summers R, Alpini G. VEGF stimulate cholangiocites proliferation through an autocrine mechanism by Calcium dependent phosphorilation of the Src/ERK1/ERK2 pathway. Gastroenterology. 2006;130:1270-82.
14. Ogasawara S, Yano H, Higaki K, Takayama A, Akiba J, Shiota K, Kojiro M. Expression of angiogenic factors, basic fibroblast growth factor and VEGF in human biliary tract carcinoma cell lines. Hepatology Research. 2001; 20(1): 97-113.
15. Alvaro D, Barbaro B, Glaser S, Francis H, Franchitto A, Ueno Y, Marzioni M, Venter J, Reichenback R, Alpini G Gaudio E. Insulin like growth factor 1 and estrogens modulate neoplastic cell growth in human cholangiocarcinoma. Hepatology 2004;40S
16. Rosen L, Gordon MS. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol 2006;4(1):suppl 1-10; quz 11-2
17. Patel, T., Worldwide trends in mortality from biliary tract malignancies. BMC Cancer., 2002. 2: p. 10.
18. Tan, C.K., et al., Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology, 1995. 108(6): p. 1908-16.
19. Kanno, N., et al., Gastrin inhibits cholangiocarcinoma growth through increased apoptosis by activation of Ca2+-dependent protein kinase C-alpha. J Hepatol, 2001. 34(2): p. 284-91.
20. Fava, G., et al., g-Aminobutyric Acid Inhibits Cholangiocarcinoma Growth by Cyclic AMP-Dependent Regulation of the Protein Kinase A/Extracellular Signal-Regulated kinase 1/2 Pathway. Cancer Res, in press, 2005.
21. Chan, C., et al., Carcinoid tumor of the hepatic duct presenting as a Klatskin tumor in an adolescent and review of world literature. Hepatogastroenterology., 2000. 47(32): p. 519-21.
22. Kanno, N., et al., Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. Hepatology, 2002. 35(6): p. 1329-40.
23. Aleffi, S., et al., Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology., 2005. 42(6): p. 1339-48.
24. Hoggard, N., et al., Leptin and leptin receptor mRNA and protein expression in the murine fetus and placenta. Proc Natl Acad Sci U S A., 1997. 94(20): p. 11073-8.
25. Wauters, M., R.V. Considine, and L.F. Van Gaal, Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol., 2000. 143(3): p. 293-311.
26. Bjorbaek, C., et al., Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem., 1997. 272(51): p. 32686-95.
27. Garofalo, C. and E. Surmacz, Leptin and cancer. J Cell Physiol., 2006. 207(1): p. 12-22.
28. Somasundar, P., et al., Leptin is a growth factor in cancer. J Surg Res., 2004. 116(2): p. 337-49.
29. Frankenberry, K.A., et al., Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg., 2004. 188(5): p. 560-5.
30. Somasundar, P., et al., Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms. Am J Surg., 2003. 186(5): p. 575-8.
31. Stattin, P., et al., Obesity and colon cancer: does leptin provide a link? Int J Cancer., 2004. 109(1): p. 149-52.
32. Aparicio, T., et al., Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min/+) mice. Gut., 2005. 54(8): p. 1136-45. Epub 2005 Apr 27.
33. Wang, X.J., et al., Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma. World J Gastroenterol., 2004. 10(17): p. 2478-81.
34. Rieger R, Oertelt S, Selmi C, Invernizzi P, Podda M, Gershwin ME. Decreased Serum Leptin Levels in Primary Biliary Cirrhosis: A Link between Metabolism and Autoimmunity? Ann N Y Acad Sci. 2005 Jun;1051:211-7.
35. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol 2004;287:G88-95.
36. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-776.
37. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, Sriuranpong V, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;3:565-576.
38. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 2005;128:1354-1368.
39. Kikuchi S, Miyagishi R, Fukazawa T, Yabe I, Miyazaki Y, Sasaki H. TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 2005;167:170-174.
40. Xu W, Liu L, Emson PC, Harrington CR, Charles IG. Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. Gene 1997;204:165-170.

Parole Chiave

COLANGIOCARCINOMA, COLESTASI, NEUROPEPTIDI, COLANGITE SCLEROSANTE PRIMARIA, LEPTINA, VEGF, PROLIFERAZIONE, APOPTOSI